Company Overview of AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP, a biopharmaceutical company, is engaged in the discovery, development, and commercialization of prescription medicines. It offers medicines primarily for the treatment of gastrointestinal, cardiovascular, metabolic, respiratory and inflammation, autoimmune, oncology, infectious, and neuroscience diseases worldwide. The company was founded in 1912 and is headquartered in Wilmington, Delaware with an additional location in London, United Kingdom. AstraZeneca Pharmaceuticals LP operates as a subsidiary of AstraZeneca PLC.
1800 Concord Pike
PO Box 15437
Wilmington, DE 19850-5437
Founded in 1912
Key Executives for AstraZeneca Pharmaceuticals LP
President of Astrazeneca US and Executive Vice President of North America
President of Astrazeneca Canada Inc.
President of US Diabetes Alliance
Vice President of Medical Affairs and US Head Medical Officer
Vice President of Human Resources
Compensation as of Fiscal Year 2014.
AstraZeneca Pharmaceuticals LP Key Developments
U.S. District Court for the Middle District of Florida Denies a Motion to Dismiss Negligence and Negligent Failure to Warn Claims Against Astrazeneca Pharms. L.P
May 2 14
The U.S. District Court for the Middle District of Florida denied a motion to dismiss negligence and negligent failure to warn claims brought by a drug consumer against AstraZeneca Pharmaceuticals L.P arising from a medical condition the consumer developed after long-term use of a medication produced by the defendant. Sharon King sued AstraZeneca Pharmaceuticals L.P., alleging negligence and negligent failure to warn arising out of injuries allegedly caused by the drugs Prilosec and Nexium, both proton pump inhibitors manufactured by AstraZeneca and used for the treatment of the esophagus. King alleged she used the two medications from 1990 until May 7, 2010, and that in 2005, she began exhibiting symptoms of hypomagnesaemia, a depletion of magnesium, which was not diagnosed until 2009. King alleged that in 2010, she learned of a correlation between hypomagnesaemia and the use of Prilosec and Nexium, and thereupon discontinued her use of the medications. King alleged that AstraZeneca became aware of the correlation between hypomagnesaemia and the use of the two medications in 2006, and at that time, began to publish warnings of the related symptoms in international markets including Scotland and the Netherlands, but did not make similar disclosures in the United States until the Food and Drug Administration revealed them in a drug safety communication on Mar. 2, 2011. AstraZeneca moved to dismiss the complaint. The district court found King provided specific factual allegations in support of her claim that the product warnings provided by AstraZeneca were inadequate. King alleged AstraZeneca knew that Prilosec and Nexium caused hypomagnesaemia as early as 2006, but failed to provide any warnings about the risk. The court found those allegations plausibly suggested the warnings provided by AstraZeneca were inadequate, and the motion to dismiss King's negligence and negligent failure to warn claims was accordingly denied. The court separately rejected AstraZeneca's contention that the complaint was subject to dismissal because King failed to distinguish between the two medications. King adequately alleged AstraZeneca designed, marketed, manufactured and sold the products in question and that both failed to warn of the risk of hypomagnesaemia. The court found that given those allegations, the combining of both medications into a single claim did not warrant dismissal.
Amarin Pharmaceuticals Ireland Limited Files Complaint Against Omthera Pharmaceuticals, Inc. and Astrazeneca Pharmaceuticals LP
Mar 4 14
Amarin Pharmaceuticals Ireland Limited announced that on March 4, 2014, the company, filed a complaint in the United States District Court for the District of Delaware against Omthera Pharmaceuticals, Inc. and AstraZeneca Pharmaceuticals LP. The suit seeks injunctive relief and monetary damages for infringement of Amarin's U.S. Patent No. 8,663,662, which was issued by the United States Patent and Trademark Office. The complaint alleges infringement of the Patent arising from the expected launch of Epanova in the United States. The Patent covers methods of lowering triglycerides by administering a pharmaceutical composition that includes amounts of EPA as free acid, and no more than about 30% DHA. Amarin intends to pursue this litigation vigorously and aggressively protect its intellectual property rights.
AstraZeneca Pharmaceuticals LP Presents at Fifth Annual ChinaBio(R) Partnering Forum 2013, May-30-2013 09:15 AM
May 21 13
AstraZeneca Pharmaceuticals LP Presents at Fifth Annual ChinaBio(R) Partnering Forum 2013, May-30-2013 09:15 AM. Venue: Shangri-La Hotel, 29 Zizhuyuan Road, Beijing 100089, China. Speakers: Augustine Yee.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|